登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：300016 证券简称：北陆药业 公告编号：2025-094 一、重要提示 本半年度报告摘要来自半年度报告全文，为全面了解本公司的经营成果、财务状况及未来发展规划，投 资者应当到证监会指定媒体仔细阅读半年度报告全文。 所有董事均已出席了审议本报告的董事会会议。 非标准审计意见提示 □适用 √不适用 董事会审议的报告期利润分配预案或公积金转增股本预案 3、公司股东数量及持股情况 单位：股 ■ 持股5%以上股东、前10名股东及前10名无限售流通股股东参与转融通业务出借股份情况 □适用 √不适用 公司计划不派发现金红利，不送红股，不以公积金转增股本。 董事会决议通过的本报告期优先股利润分配预案 □适用 √不适用 公司是否需追溯调整或重述以前年度会计数据 □是 √否 ■ □适用 √不适用 前10名股东及前10名无限售流通股股东因转融通出借/归还原因导致较上期发生变化 □适用 √不适用 公司是否具有表决权差异安排 □是 √否 二、公司基本情况 1、公司简介 ■ 2、主要会计数据和财务指标 4、控股股东或实际控制人变更情况 控股股东报告期内变更 □适用 √不适用 ...

Financial Performance - In Q1 2025, Beilu Pharmaceutical achieved operating revenue of 28,268.07 million yuan, a year-on-year increase of 36.23% [2] - The net profit attributable to shareholders increased by 26.13%, amounting to 1,308.80 million yuan, while the net profit excluding non-recurring gains and losses rose by 14.34% [2] Business Growth Drivers - The growth in Q1 2025 was primarily driven by three core segments: chemical generic drugs, traditional Chinese medicine, and overseas markets [3] - The acquisition of Tianyuan Pharmaceutical has led to significant integration efforts, enhancing marketing strategies and operational efficiency [3] Market Expansion - The company plans to leverage EU and Brazil GMP certifications to accelerate market development in these regions, aiming to enhance international brand influence and market share [4][5] - In Q1 2025, the subsidiary Haichang Pharmaceutical's iodinated contrast agent received approval for sale in South Korea, and the iodinated injection was approved in the EU [4] Financial Structure - The debt ratio reached 42.49% in Q1 2025, an increase attributed to a new long-term loan of 160 million yuan for acquiring 80% of Tianyuan Pharmaceutical [4] - Future plans include optimizing the capital structure and reducing the debt ratio through diversified financing channels [4] Subsidiary Developments - The company has established several wholly-owned subsidiaries, including: - Beijing Aipai Kesi Pharmaceutical R&D Co., focusing on product development and technological upgrades [5] - Anhui Luying Pharmaceutical Co., assisting in operations at the Bozhou production base [5] - Hong Kong Yuan Zhi Pharmaceutical Co., serving as an overseas window for market expansion [5] Product and Market Strategy - The company is actively promoting the Jiuwei Zhenxin Granules to enhance market share, despite stable procurement prices for key ingredients [5] - The company has not yet entered the veterinary medicine sector, focusing instead on prescription drugs [7]